Raju Prasad - 06 Jan 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
06 Jan 2026
Net transactions value
-$451,006
Form type
4
Filing time
08 Jan 2026, 17:35:03 UTC
Previous filing
23 Dec 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Prasad Raju Chief Financial Officer C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON /s/ Elizabeth Ryland Waldinger, attorney-in-fact 08 Jan 2026 0001968317

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $1,054,749 +23,361 +345% $45.15 30,128 06 Jan 2026 Direct
transaction CRSP Common Shares Options Exercise $280,881 +6,339 +21% $44.31 36,467 06 Jan 2026 Direct
transaction CRSP Common Shares Sale $1,139,386 -18,933 -52% $60.18 17,534 06 Jan 2026 Direct F1, F2
transaction CRSP Common Shares Sale $300,240 -5,004 -29% $60.00 12,530 06 Jan 2026 Direct F1
transaction CRSP Common Shares Sale $347,010 -5,763 -46% $60.21 6,767 06 Jan 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -23,361 -23% $0.000000 76,639 06 Jan 2026 Common Shares 23,361 $45.15 Direct F4
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -6,339 -46% $0.000000 7,493 06 Jan 2026 Common Shares 6,339 $44.31 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
F5 This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.